Search clinical trials for: Relapsed and refractory multiple myeloma; CAR-T

Total 471977 results

Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Nanjing IASO Biotechnology Co., Ltd.
Ruijin Hospital

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)

Relapsed/Refractory Multiple Myeloma

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Medical College of Wisconsin

Recruiting

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaborators

Recruiting

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
UNC Lineberger Comprehensive Cancer Center

Recruiting

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Immune System Diseases | Multiple Myeloma

United States
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Juno Therapeutics, a Subsidiary of Celgene

Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

United States
Novartis Pharmaceuticals

Active, not recruiting

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Saudi Arabia, Germany, Singapore, Italy, France, Israel, United Kingdom, Japan, Australia, Spain, Brazil, United States, Greece, Canada
Thomas Martin, MD
University of California, Davis; Actavis Inc.; Eugia Pharma Specialities Limited

Active, not recruiting

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Zhujiang Hospital
The Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)

Relapsed/Refractory Multiple Myeloma(MM)

China
Celgene

Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

Multiple Myeloma

United States, Canada, Belgium, France, Germany, Italy, Japan, Spain
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
Nektar Therapeutics

Completed

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Multiple Myeloma | Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
Nanjing Legend Biotech Co.
Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaborators

Active, not recruiting

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

Refractory or Relapsed Multiple Myeloma
Chongqing Precision Biotech Co., Ltd

Enrolling by invitation

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
The Sixth Affiliated Hospital of Wenzhou Medical...
Zhejiang Qixin Biotech

Unknown

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

RRMM

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
First Affiliated Hospital of Zhejiang University

Unknown

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Myeloma

China
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases (BAH247)

Autoimmune Diseases | Systemic Lupus Erythematosus | Sjogren's Syndrome | Systemic Lupus Erythematosus Acute

China
Janssen Research & Development, LLC

Not yet recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain

Search clinical trials for: Relapsed and refractory multiple myeloma; CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations